P. Vermersch Et Al. , "Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies," 4th Congress of the European-Academy-of-Neurology (EAN) , vol.25, Lisbon, Portugal, pp.190, 2018
Vermersch, P. Et Al. 2018. Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies. 4th Congress of the European-Academy-of-Neurology (EAN) , (Lisbon, Portugal), 190.
Vermersch, P., Comi, G., Siva, A., Oreja-Guevara, C., Wiendl, H., Van Wijmeersch, B., ... Eralinna, J. -.(2018). Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies . 4th Congress of the European-Academy-of-Neurology (EAN) (pp.190). Lisbon, Portugal
Vermersch, P. Et Al. "Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies," 4th Congress of the European-Academy-of-Neurology (EAN), Lisbon, Portugal, 2018
Vermersch, P. Et Al. "Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies." 4th Congress of the European-Academy-of-Neurology (EAN) , Lisbon, Portugal, pp.190, 2018
Vermersch, P. Et Al. (2018) . "Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies." 4th Congress of the European-Academy-of-Neurology (EAN) , Lisbon, Portugal, p.190.
@conferencepaper{conferencepaper, author={P. Vermersch Et Al. }, title={Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies}, congress name={4th Congress of the European-Academy-of-Neurology (EAN)}, city={Lisbon}, country={Portugal}, year={2018}, pages={190} }